Agenus to advance three checkpoint modulator antibodies into development Pharmaceutical Business Review The parties also have ongoing programs to discover and develop other immune checkpoint modulator antibodies, including OX40 agonists and antagonists of LAG-3, TIM-3 and PD-1. Agenus chief scientific officer Dr Robert B Stein noted GITR, a checkpoint ... Ludwig and Agenus to advance three checkpoint modulator antibodies into ... Agenus Inc (AGEN) news: Agenus' CEO Discusses Q4 2013 Results - Earnings ... Agenus reports net loss attributable to common stockholders of $5.8 million ... |
